-
Peaceful Repeat Vote in Douglas Ward 3 Amid Heightened Security
-
‘They want silence’: how the film NAZA is shaking Israel
-
Belgian Ambassador Marks King’s Day in Athens Amidst Strong Bilateral Trade Ties
-
Dún Laoghaire-Rathdown €335m Budget Faces Mixed Reaction Over Housing and Cost of Living
-
Rediff.com IPO Risks: Gmail Dominance and New Business Ventures
-
BING X: 22,624.66 SNC have disappeared at BingX – how safe are tokens on BingX? Will BingX’s MiCAR licence be suspended?
-
Dubai Police Expand Luxury Patrol Fleet with 525-hp Defender
-
Iran Strikes US Sites in Kuwait Following US Airstrikes on Qeshm Island
-
NuRAN Wireless Raises First Two Towers in Benin as 4G Rollout Beats Expectations in Cameroon and Ivory Coast
-
LHH ICEO Research Led by Harvard Business School Professor Maps Four Paths for Work Beyond the C-Suite
-
ESGold Expands Montauban Gold-Silver Property to Approximately 26,787 Hectares Through Strategic Claim Staking
-
Wedgewood Weddings Acquires Swan Lake Overlook, Where Alpacas, Deer, and Mountain Views Join the Guest List
-
DSS Announces Completion of Impact Biomedical Business Combination with Zoar Limited
-
Newsmax Expands Over-the-Air Reach with HC2 Broadcasting Distribution Agreement for Newsmax2
-
Impala and Philanthropy Southwest Launch Southwest Hub, Mapping Philanthropy Across Eight States
-
HTB Activ(TM) Trial Demonstrates Significant Improvement in Cognitive Abilities
-
Nixxy Announces 1-for-20 Reverse Stock Split
-
IGC Pharma Completes Dosing in Phase 2 CALMA Trial of IGC-AD1 for Agitation in Alzheimer's Dementia
-
The IRS Watchdog Just Published Its FY 2027 Challenges List - Clear Start Tax Explains Why Agency Strain Rarely Slows Down Collection Notices
-
Who Does the Best Deep Plane Facelift in Oklahoma?
-
Tocvan Defines Priority Gold Target Areas at Gran Pilar From Project-Wide Soil Sampling and Geologic Mapping; 225 Soils at or Above 100 ppb Gold
-
Rockhaven Announces Successful Completion of 2026 Klaza Bulk Sample Program
-
Silver Storm to Attend the 121 Mining Investment Conference in London, UK
-
American Resources Corporation Provides Strategic Business and Financial Reporting Update
-
Who Does the Best Deep Plane Facelift in Sarasota?
-
Jumia Reports Third Quarter 2026 Results
-
Ameriwest Advances Its Copper Focused Strategy Through Proposed Sale of Railroad Valley to Pure Energy Minerals
-
1933 Industries Completes LED Lighting Retrofit at Its 68,000 Sq. Ft. Cannabis Cultivation Facility in Las Vegas, Nevada - Ranks #3 in Cannabis Flower Sales
-
AbTherx Licenses Atlas(TM) Platform to Athenova Therapeutics for Next-Generation Targeted Alpha Radiopharmaceutical Discovery
-
DataMeds AI Subsidiary Helomics, Inc. Announces Cancer Target Discovery and Anticancer Peptides Drug Development Partnership With DiaGen AI, Inc.
-
What to Do When Two Households Become One
-
SmartBuyerAI Gives Car Buyers an Itemized Check of Dealer Offers as FTC Steps Up Price Transparency Enforcement
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 18
-
Fulcrum Metals PLC Announces Uranium Readings up to 0.42% U(3)O(8) at Charlot-Neely
-
Srixon Announces Buy 2, Get 1 Free Golf Ball Promotion
-
Ondas and Aston Martin Aramco Formula One Team Launch Multi-Year Partnership Built for "Speed to Decision"
-
Who Does the Best Testosterone Replacement Therapy in Las Vegas?
-
CMP 2026-2027 Nonprofit Leadership Pulse Check
-
Nexteer's HMDD Wins Innovation Awards from PACE Pilot, CES and AutoTech Breakthrough
-
Coa Wealth Launches AI-Powered Software That Functions as a Private Investment Office for Individual Investors and Families
-
More Than Keyboards: Epomaker Brings Its Gaming World to G-STAR 2026
-
Who Is the Best Spanish-Speaking Private Investigator in Sacramento?
-
Healixa Turns Patents Into Products: FrostPulse(TM) Delivered and Five Eternal Spring(TM) Units Enter Production
-
Leggett Dynamics Wins 2026 Automotive News PACE Pilot Award For Smart Brushless Motor
-
Cosmos Health Reports Record Nine-Month Revenue of $53.6 Million, Up 18%; Q3 Gross Margin Up 465 Basis Points Sequentially; Total Debt Down 34% and Stockholders' Equity Up 21% Since Year-End
-
Nearly Half of Transformation Initiatives Face a 'Momentum Gap' That Puts Value at Risk, NSP & Company Study Finds
-
CXAI Expands Agentic AI Reach into Mid-Market Through EngineRoom's Simpro Partnership
-
cbdMD Applauds Introduction of the Bipartisan Hemp Guardrails Act, Calling It a Win for Consumer Safety, American Jobs and Tax Revenue
-
Agency Guacamole's 10th B.L.N.D. Event Brought Industry Leaders Together for a Conversation on the Evolution of Diversity and Inclusion in Beauty
-
From Pilot to Production: InHand Networks' Practical Approach to Industrial Edge AI
What's the deal with peptides? The hyped market under US review
Glowing skin, deeper sleep, stronger muscles, an alert mind?
Such are the enticing promises of peptides, an increasingly buzzy class of substances touted by influencers and celebrities as the key to an optimized life.
Starting Thursday, a US review panel convened by the Food and Drug Administration is to consider whether seven of these peptides should be recommended for compounding -- when pharmacists or outsourcing facilities create custom drugs -- as interest in them surges.
Many medical experts have warned against that recommendation, citing a lack of evidence.
"There's just not enough clinical data to say whether these peptides are safe and effective," said Alexander Weber, an orthopedic surgeon and chief of sports medicine at the University of Southern California.
And yet, "peptides come up with my conversations with patients every single day," he told AFP.
The substances under review -- including BPC-157, TB-500 and Semax -- are among those Joe Biden's administration restricted from compounding, notably over lack of human clinical trial data.
But that hasn't thwarted use in many cases. Substances can be purchased online from chemical suppliers "for lab use only."
Wellness influencers, industry advocates, and Robert F. Kennedy Jr -- President Donald Trump's health chief, who says he has used peptides to treat injuries -- say the restrictions have fueled gray markets of overseas suppliers with no oversight or standards.
"With the gray market you have no idea if you're getting a good product," Kennedy said in an interview this year with podcast host Joe Rogan. "And a lot of this stuff that we've looked at is just very, very substandard."
Medical experts accuse Kennedy of packing the FDA advisory panel with people who have strong ties to the peptide industry, given his personal interest in the products.
"In ordinary circumstances, I would say that these products are dead," Peter Lurie, president of the Center for Science in the Public Interest and a former FDA official, told AFP.
"But given the way that the committee is stacked," he said, "I don't have that confidence at all."
- 'Alarming safety concern' -
Peptides are short chains of amino acids, which are the building blocks of proteins.
They are naturally occuring in the body, signaling molecules that dictate major physiological processes like tissue repair or metabolism.
Insulin is a peptide, for example.
GLP-1 medications like Ozempic are also peptides: they mimic a naturally occurring molecule that regulates appetite, blood sugar and digestion.
Both of those treatments are well-studied.
But the synthetic peptides touted by influencers and biohackers, which are often injectable, are not.
Such substances have not undergone the kind of large-scale trials the FDA would normally require to establish safety and efficacy.
The FDA's own career scientists have published documents outlining concerns that even if peptides are trendy, evidence to support loosening restrictions is still inadequate.
Their conclusions mirror those of a white paper jointly published in May by the nonprofit ECRI and the Institute for Safe Medication Practices (ISMP).
"The commercial market has grown faster than the clinical evidence base," the paper read, and "the absence of adequate clinical evidence for use in humans is an alarming safety concern."
Rita Jew, the ISMP president, told AFP "there's no new information that will make us feel comfortable" that the seven peptides should be authorizied for compounding.
- Genie out of the bottle? -
Ed Lee is an Orlando-based endocrinologist who is hopeful for compounding approvals, especially for BPC-157, which is popular in the wellness community for its purported ability to repair tissues, including muscles and ligaments.
Lee co-founded the "Clinical Peptides Society" and started a petition called "Save Peptides" which has garnered nearly 10,000 signatures and urges federal legislators to loosen restrictions on peptides.
"I don't know how they're going to put the genie back in the bottle," Lee told AFP.
But for Lurie, the argument that demand should inevitably lead to a stamp of approval falls short given the "extremely thin science."
"If at the end of the day these products are approved, I see nothing good coming out of it," he said.
Weber said his patients have relayed positive anecdotes regarding peptide use -- but cautioned such anecdotes are not enough to guide use more broadly, without deeper research.
"There's a lot of bias that goes into that two cents," Weber said.
"If you're paying for something, you want it to work."
O.Brown--AT